Business Context and Reporting Period
This Form 8-K, dated November 7, 2023, reports the consummation of a business combination between Data Knights Acquisition Corp. (a special purpose acquisition company) and OneMedNet Solutions Corporation. Following shareholder approval, Data Knights Merger Sub, Inc. merged with and into OneMedNet, with OneMedNet surviving as a wholly-owned subsidiary. The combined entity is now named OneMedNet Corporation and trades on the Nasdaq Capital Market under the symbol ONMD (common stock) and ONMDW (warrants).
Key Financial Metrics and Capital Structure
The filing details the capital structure and financing events surrounding the closing but does not provide specific revenue, profit, or cash flow figures for the combined entity in this document; such data is incorporated by reference from the Proxy Statement/Prospectus.
- Total Merger Consideration: Approximately $200 million.
- PIPE Financing: The company secured $1.5 million in private investment through the issuance of senior secured convertible notes (PIPE Notes) to accredited investors. These notes are convertible at $10.00 per share or 92.5% of the lowest volume-weighted average trading price over the preceding 10 trading days.
- Redemptions: Public holders redeemed 1,600,741 shares of Data Knights Class A Common Stock for a pro rata portion of the trust account funds.
- Post-Closing Share Ownership (approximate):
- Former OneMedNet security holders: 61.992%
- Former convertible note holders: 16.24%
- Sponsor and affiliates: 15.1%
- Public stockholders: 0.35%
- PIPE investors: 0.46%
- Outstanding Shares: 32,263,342 shares of common stock as of November 8, 2023.
Material Changes Versus Prior Period
The primary material change is the transition from a shell company (Data Knights) to an operating entity (OneMedNet Corporation). Key structural changes include:
- Corporate Status: Data Knights ceased being a shell company upon closing.
- Securities Conversion: All Data Knights common stock and warrants automatically converted into OneMedNet common stock and warrants with substantively identical terms.
- Debt Conversion: Former convertible note holders received 5,238,800 shares of common stock upon conversion of their notes.
- Management Changes: The board and executive team were reconstituted. Former Data Knights directors and officers (Barry Anderson, Firdauz Edmin bin Mokhtar, Syed Musheer Ahmed, and Annie Damit Undikai) resigned.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing contains forward-looking statements regarding future financial results, market size, and growth plans. Management cautions that actual results may differ materially due to uncertainties in realizing business combination benefits, client demand, and regulatory changes. No specific numerical revenue or earnings guidance is provided in this text.
Risks and Contingencies:
- Forward-Looking Statements: Subject to significant business, economic, and competitive uncertainties.
- Operating History: Risks related to OneMedNet's limited operating history and the timing of business milestones.
- Internal Controls: Risk regarding the ability to develop and maintain effective internal controls.
Unusual Items / Agreements:
- Lock-Up Agreements: Company holders and the Sponsor are subject to lock-up periods (generally six months from closing) restricting the sale of shares, with exceptions for specific corporate transactions or if the stock price exceeds $12.00 for 20 trading days within a 30-day period (for Sponsor founder shares).
- Executive Compensation: New employment agreements were executed for key officers (Paul Casey, Aaron Green, Lisa Embree) with salaries ranging from $144,000 to $350,000, performance bonuses, and equity grants. Severance packages of 3 to 6 months' salary are available upon termination without cause or for good reason.
- Equity Incentive Plan: A 2022 Equity Incentive Plan was approved, reserving 10% of post-combination outstanding shares for issuance.
Important Facts for Investor Verification
- Trading Symbols: Verify trading activity under ONMD (stock) and ONMDW (warrants) on the Nasdaq Capital Market starting November 8, 2023.
- Financial Statements: Review the Unaudited Pro Forma Condensed Combined Financial Statements (Exhibit 99.1) and the Proxy Statement/Prospectus (effective September 22, 2023) for detailed historical and projected financial data, as this 8-K does not contain the full income statement or balance sheet.
- PIPE Note Terms: Confirm the conversion mechanics of the $1.5 million PIPE Notes, specifically the "lower of" conversion price provision ($10.00 vs. 92.5% of VWAP).
- Ownership Concentration: Note that former OneMedNet security holders and former convertible note holders collectively own approximately 78% of the outstanding shares immediately post-closing.
- Lock-Up Expirations: Monitor the six-month lock-up expiration date (approximately May 2024) for potential selling pressure from insiders and the Sponsor.